Protocol Ledger

NCT05751668 · Phase II · ACTIVE NOT RECRUITING

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel

Interventional Phase II clinical trial protocol NCT05751668 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-02 Enrollment: 7 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05751668
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)7 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05751668
Protocol FieldVerified Registry Value
NCT IdentifierNCT05751668
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment7 participants (ACTUAL)
Registered Start Date2023-11-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI